NOVARTIS logo.jpg
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
16 sept. 2024 04h15 HE | Novartis Pharma AG
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain...
RGB _ RENOVARO _ LOGO _ with word mark.png
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
13 sept. 2024 09h00 HE | Renovaro Inc
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
12 sept. 2024 16h05 HE | Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Le PIONeeR Project p
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
12 sept. 2024 04h21 HE | The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
logoPioneer plein.png
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
12 sept. 2024 04h21 HE | The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
RAHF logo square mixed.png
Rita and Alex Hillman Foundation Announces $500,000 in Funding for Nine Projects to Improve Serious Illness and End of Life Care
10 sept. 2024 11h01 HE | Rita & Alex Hillman Foundation
RITA AND ALEX HILLMAN FOUNDATION ANNOUNCES $500,000 IN GRANTS TO IMPROVE SERIOUS ILLNESS AND END OF LIFE CARE, WITH THE ARTHUR VINING DAVIS FOUNDATIONS.
purple-logo2020.png
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
10 sept. 2024 07h00 HE | Purple Biotech Ltd.
REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
10 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
RNAZ White background cropped.jpg
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Movember_Primary Logo_Black.jpg
Movember Announces Three Year Partnership With the International Society for Sexual Medicine
04 sept. 2024 07h00 HE | Movember Canada
Movember is kicking off Prostate Cancer Awareness Month by announcing a new three-year partnership with the International Society for Sexual Medicine.